4.6 Article

Long-term benefits in quality of life after unilateral thalamic deep brain stimulation for essential tremor Clinical article

Journal

JOURNAL OF NEUROSURGERY
Volume 117, Issue 1, Pages 156-161

Publisher

AMER ASSOC NEUROLOGICAL SURGEONS
DOI: 10.3171/2012.3.JNS112316

Keywords

essential tremor; deep brain stimulation; quality of life; thalamic stimulation; functional neurosurgery

Funding

  1. Novartis
  2. Impax
  3. Merck Serono
  4. Boehringer Ingelheim
  5. Schering Plough
  6. Adamas
  7. Phytopharm
  8. Biotie
  9. Allon
  10. Acadia
  11. Xenoport

Ask authors/readers for more resources

Object. The goal of this study was to evaluate short- and long-term benefits in quality of life (QOL) after unilateral deep brain stimulation (DBS) for essential tremor (ET). Methods. Patients who received unilateral DBS of the ventral intermediate nucleus of the thalamus between 1997 and 2010 and who had at least 1 follow-up evaluation at least I year after surgery were included. Their QOL was assessed with the Parkinson Disease Questionnaire-39 (PDQ-39), and ET was measured with the Fahn-Tolosa-Marin tremor rating scale (TRS) prior to surgery and then postoperatively with the stimulation in the on mode. Results. Ninety-one patients (78 at 1 year; 42 at 2-7 years [mean 4 years]; and 22 at > 7-12 years [mean 9 years]) were included in the analysis. The TRS total, targeted tremor, and activities of daily living (ADL) scores were significantly improved compared with presurgical scores up to 12 years. The PDQ-39 ADL, emotional well-being, stigma, and total scores were significantly improved up to 7 years after surgery compared with presurgical scores. At the longest follow-up, only the PDQ-39 stigma score was significantly improved, and the PDQ-39 mobility score was significantly worsened. Conclusions. Unilateral thalamic stimulation significantly reduces ET and improves ADL scores for up to 12 years after surgery, as measured by the TRS. The PDQ-39 total score and the domains of ADL, emotional well-being, and stigma were significantly improved up to 7 years. Although scores were improved compared with presurgery, other than stigma, these benefits did not remain significant at the longest (up to 12 years) follow-up, probably related in part to changes due to aging and comorbidities. (http://thejns.org/doi/abs/10.3171/2012.3.JNS112316)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available